GENFIT (GNFT) Competitors $3.82 -0.07 (-1.80%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNFT vs. REPL, VIR, SION, GYRE, PHAT, ANAB, IMTX, TRVI, NUVB, and DAWNShould you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include Replimune Group (REPL), Vir Biotechnology (VIR), Sionna Therapeutics (SION), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), Immatics (IMTX), Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. GENFIT vs. Its Competitors Replimune Group Vir Biotechnology Sionna Therapeutics Gyre Therapeutics Phathom Pharmaceuticals AnaptysBio Immatics Trevi Therapeutics Nuvation Bio Day One Biopharmaceuticals GENFIT (NASDAQ:GNFT) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Do insiders & institutionals believe in GNFT or REPL? 2.2% of GENFIT shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 4.2% of GENFIT shares are owned by company insiders. Comparatively, 8.8% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is GNFT or REPL more profitable? GENFIT's return on equity of 0.00% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets GENFITN/A N/A N/A Replimune Group N/A -57.98%-45.21% Which has more volatility & risk, GNFT or REPL? GENFIT has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Which has stronger valuation & earnings, GNFT or REPL? GENFIT has higher revenue and earnings than Replimune Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGENFIT$76.77M2.49$1.63MN/AN/AReplimune GroupN/AN/A-$247.30M-$3.07-3.08 Does the media favor GNFT or REPL? In the previous week, Replimune Group had 5 more articles in the media than GENFIT. MarketBeat recorded 5 mentions for Replimune Group and 0 mentions for GENFIT. Replimune Group's average media sentiment score of 0.37 beat GENFIT's score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media. Company Overall Sentiment GENFIT Neutral Replimune Group Neutral Do analysts recommend GNFT or REPL? GENFIT currently has a consensus target price of $13.00, indicating a potential upside of 240.31%. Replimune Group has a consensus target price of $20.83, indicating a potential upside of 120.46%. Given GENFIT's higher possible upside, analysts clearly believe GENFIT is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryReplimune Group beats GENFIT on 7 of the 13 factors compared between the two stocks. Get GENFIT News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGENFITMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$191M$2.89B$5.53B$9.02BDividend YieldN/A2.44%5.22%3.99%P/E RatioN/A21.7127.7020.25Price / Sales2.49283.26419.56119.26Price / Cash55.3341.7026.2128.59Price / Book2.557.538.035.65Net Income$1.63M-$55.14M$3.18B$249.15M7 Day Performance2.55%4.22%2.88%2.91%1 Month Performance-8.15%0.91%1.67%4.11%1 Year Performance-8.17%5.40%34.39%20.98% GENFIT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGENFIT1.9744 of 5 stars$3.82-1.8%$13.00+240.3%-8.2%$191M$76.77M0.00120Positive NewsREPLReplimune Group4.1737 of 5 stars$9.29-0.4%$20.83+124.3%+16.5%$719.22MN/A-3.03210VIRVir Biotechnology3.2017 of 5 stars$5.04-2.5%$32.86+551.9%-35.6%$714.69M$74.21M-1.19580News CoverageSIONSionna TherapeuticsN/A$17.35+9.5%$38.50+121.9%N/A$698.93MN/A0.0035Positive NewsInsider TradeGYREGyre Therapeutics0.0779 of 5 stars$7.35-0.9%N/A-34.5%$695.68M$105.76M367.6840PHATPhathom Pharmaceuticals3.4686 of 5 stars$9.59-1.5%$17.50+82.5%-14.9%$679.99M$55.25M-1.83110ANABAnaptysBio2.286 of 5 stars$22.20-1.2%$42.38+90.9%-2.8%$660.18M$91.28M-4.58100IMTXImmatics2.4223 of 5 stars$5.38-0.9%$14.67+172.6%-52.0%$660.02M$168.65M-31.65260Positive NewsTRVITrevi Therapeutics3.2765 of 5 stars$5.47-2.7%$20.29+270.9%+128.5%$659.19MN/A-12.1620NUVBNuvation Bio3.4373 of 5 stars$1.96+1.3%$7.17+266.6%-31.2%$656.71M$7.87M-0.8360Gap UpHigh Trading VolumeDAWNDay One Biopharmaceuticals1.7011 of 5 stars$6.50+0.5%$30.57+370.3%-50.4%$655.82M$131.16M-9.1560Upcoming Earnings Related Companies and Tools Related Companies Replimune Group Alternatives Vir Biotechnology Alternatives Sionna Therapeutics Alternatives Gyre Therapeutics Alternatives Phathom Pharmaceuticals Alternatives AnaptysBio Alternatives Immatics Alternatives Trevi Therapeutics Alternatives Nuvation Bio Alternatives Day One Biopharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNFT) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENFIT S.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GENFIT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
